Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
Atara Biotherapeutics (NASDAQ: ATRA) is a leading innovator in cellular immunotherapy, developing transformative treatments for cancer and autoimmune diseases. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Access timely updates on T-cell therapy advancements, including CAR T platform developments and collaboration progress with Memorial Sloan Kettering Cancer Center. Our curated collection features press releases about product candidates in oncology and autoimmune research, financial disclosures, and manufacturing updates.
Key content includes analysis of Phase 1-3 trial outcomes, FDA communications regarding allogeneic therapies, and licensing agreements supporting ATRA's pipeline development. Bookmark this page for direct access to primary source materials and objective reporting on the company's progress in addressing unmet medical needs through innovative immunotherapies.
Atara Biotherapeutics (Nasdaq: ATRA) announced advancements in its T-cell immunotherapy research at the TCT 2021 meeting, including data on its lead candidate, tab-cel®.
Key points include consistent therapeutic activity across tab-cel® production, clinical studies in EBV-related diseases, and the advancement of ATA3219, a next-generation CAR T therapy. Further, a novel testing solution for non-engineered therapies, developed with CareDx, aims to enhance therapeutic monitoring.
The company remains on track for a Biologics License Application in Q3 2021, based on promising interim trial data.
Atara Biotherapeutics (Nasdaq: ATRA) has announced six poster presentations at the upcoming Transplantation & Cellular Therapy (TCT) Meeting, occurring virtually from February 8-12, 2021. The presentations will focus on Atara's innovative allogeneic EBV T-cell platform, highlighting the mechanism of action of tabelecleucel (tab-cel®) and an assay for non-engineered T-cell therapies. Key posters include studies on tabelecleucel's clinical efficacy and the development of a new CAR-T therapy, ATA3219, without gene editing.
Atara Biotherapeutics (Nasdaq: ATRA) revealed its strategic priorities and progress at the upcoming J.P. Morgan Healthcare Conference on January 13, 2021. CEO Pascal Touchon emphasized significant advancements in 2020, particularly for its lead candidate tab-cel® for EBV-positive post-transplant lymphoproliferative disease. Key milestones include the completion of the BLA rolling submission and anticipated approvals in the U.S. and EU in 2022. Additionally, Atara plans to provide updates on ATA188 for progressive MS and CAR T programs throughout the year.
Atara Biotherapeutics (Nasdaq: ATRA) announced that CEO Pascal Touchon will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13 at 1:30 PM PST/4:30 PM EST. This event will showcase Atara's advancements in T-cell immunotherapy, particularly its allogeneic EBV T-cell platform aimed at treating serious diseases like solid tumors and autoimmune disorders. A live audio webcast will be available on atarabio.com, with a recorded version accessible for 30 days post-event.
Atara Biotherapeutics (Nasdaq: ATRA) has not yet initiated the Biologics License Application (BLA) for tab-cel® (tabelecleucel), under Phase 3 development for EBV-positive post-transplant lymphoproliferative disease. The Company awaits a procedural decision from the FDA regarding historical data presentation in the BLA. Despite the delay, Atara remains on track to complete the BLA filing in Q3 2021, with an objective response rate of 50% reported in the pivotal study. Ongoing discussions with the FDA are described as constructive.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced a public offering of 5,102,041 shares at $24.50 each and pre-funded warrants for 2,040,816 shares at $24.4999, totaling approximately $175 million in gross proceeds. The offering is set to close on December 11, 2020, pending customary conditions. Citigroup, Evercore ISI, and Mizuho Securities serve as joint book-running managers, with an option for underwriters to purchase an additional 1,071,428 shares. The offering is conducted under a previously filed registration statement with the SEC.
Atara Biotherapeutics (Nasdaq: ATRA) has initiated a public offering of $150 million in common stock, with a potential additional $22.5 million from underwriters. The offering is subject to market conditions, and there are no guarantees regarding its completion or terms. The shares will be sold by Atara Biotherapeutics, leveraging a previously filed shelf registration statement with the SEC. Citigroup, Evercore ISI, and Mizuho Securities are acting as joint book-running managers for this offering.
Atara Biotherapeutics (Nasdaq: ATRA) announced the first preclinical evaluation of ATA3219, a novel off-the-shelf CAR T-cell therapy targeting CD19, and data from its Phase II study of tab-cel® for EBV-driven diseases. The results showcased ATA3219's potent antitumor activity and safety in preclinical models. Atara plans to submit an IND for ATA3219 in 2021 following a successful FDA meeting. Additionally, tab-cel® demonstrated high response rates in patients with life-threatening EBV viremia, with an overall survival rate of 100% at one year.
Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) have entered a global license agreement for mesothelin-directed CAR T-cell therapies targeting solid tumors. This collaboration involves the development candidate ATA3271 and an autologous version, ATA2271. Atara will oversee IND-enabling studies while Bayer manages the IND submission and clinical development. Atara receives an upfront payment of $60 million and can earn up to $610 million in milestones plus royalties on net sales. This partnership aims to enhance the development of off-the-shelf CAR T-cell therapies for challenging cancer types.
Atara Biotherapeutics, a leader in T-cell immunotherapy, has announced participation in two upcoming virtual conferences. The Stifel 2020 Virtual Healthcare Conference is set for November 18, 2020, featuring a fireside chat with CEO Pascal Touchon. The Evercore ISI 3rd Annual Virtual HealthCONx Conference will take place on December 2, 2020, with chats including Pascal Touchon and Jakob Dupont, Global Head of Research and Development. Both events will be accessible via live webcasts on the company's website, with archived replays available for 14 days.
